Transgenic mouse models of spinal and bulbar muscular atrophy (SBMA)

Cytogenetic and Genome Research

Volumn 100, Issue 1-4, 2003, Pages 243-251

  Katsuno, M ^a   Adachi, H ^a   Inukai, A ^a   Sobue, G ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; HISTONE DEACETYLASE INHIBITOR; POLYGLUTAMINE; RECOMBINANT HORMONE; TRINUCLEOTIDE;

BRAIN STEM; BULBAR PARALYSIS; CELL NUCLEUS INCLUSION BODY; DISEASE CARRIER; DISEASE MODEL; EXON; GENE FUNCTION; GENE MUTATION; GENE STRUCTURE; HORMONAL THERAPY; HUMAN; KENNEDY DISEASE; MOTOR NEURON DISEASE; NEUROPATHOLOGY; NONHUMAN; NUCLEOTIDE REPEAT; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; REVIEW; SEX DIFFERENCE; SPINAL CORD; SYMPTOM; TRANSGENIC MOUSE;

ANIMALS; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; MALE; MICE; MICE, TRANSGENIC; MUSCULAR ATROPHY, SPINAL; PHENOTYPE; RECEPTORS, ANDROGEN; SEX FACTORS; TRINUCLEOTIDE REPEAT EXPANSION;

MUS MUSCULUS;

EID: 0344531037     PISSN: 14248581     EISSN: None     Source Type: Journal    
DOI: 10.1159/000072860     Document Type: Review

References (65)

1. Abel A, et al: Expression of expanded repeat androgen receptor produces neurologic disease in transgenic mice. Hum molec Genet 10:107-116 (2001).
2. Adachi H, et al: Transgenic mice with an expanded CAG repeat controlled by the human AR promoter show polyglutamine nuclear inclusions and neuronal dysfunction without neuronal cell death. Hum molec Genet 10:1039-1048 (2001).
3. Adachi H, et al: HSP70 chaperone over-expression ameliorates phenotypes of the SBMA transgenic mouse model by reducing nuclear-localized mutant AR protein. J Neurosci 23:2203-2211 (2003).
4. Bingham PM, et al: Stability of an expanded trinucleotide repeat in the androgen receptor gene in transgenic mice. Nature Genet 9:191-196 (1995).
5. Brooks BP, et al: Characterization of an expanded glutamine repeat androgen receptor in a neuronal cell culture system. Neurobiol Dis 3:313-323 (1997).
6. Burright EN, et al: SCA1 transgenic mice: a model for neurodegeneration caused by an expanded CAG trinucleotide repeat. Cell 82:937-948 (1995).
7. Cummings CJ, et al: Over-expression of inducible HSP70 chaperone suppresses neuropathology and improves motor function in SCA1 mice. Hum molec Genet 10:1511-1518 (2001).
8. Danek A, et al: Decrease in androgen binding and effect of androgen treatment in a case of X-linked bulbospinal neuronopathy. Clin Investig 72:892-897 (1994).
9. DiFiglia M, et al: Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 277:1990-1993 (1997).
10. Doyu M, et al: Severity of X-linked recessive bulbospinal neuronopathy correlates with size of the tandem CAG repeat in androgen receptor gene. Ann Neurol 32:707-10 (1992).
11. Doyu M, et al: Androgen receptor mRNA with increased size of tandem CAG repeat is widely expressed in the neural and nonneural tissues of X-linked recessive bulbospinal neuronopathy. J Neurol Sci 127:43-47 (1994).
12. Dragatsis I, et al: Inactivation of Hdh in the brain and testis results in progressive neurodegeneration and sterility in mice. Nature Genet 26:300-306 (2000).
13. Goldenberg JN, et al: Testosterone therapy and the pathogenesis of Kennedy's disease (X-linked bulbospinal muscular atrophy). J Neurol Sci 135:158-161 (1996).
14. Gottlieb B, et al: Androgen insensitivity. Am J med Genet 89:210-217 (1999).
15. Hackam AS, Singaraja R, Zhang T, Gan L, Hayden MR: In vitro evidence for both the nucleus and cytoplasm as subcellular sites of pathogenesis in Huntington's disease. Hum molec Genet. 8:25-33 (1999).
16. Hockly E, et al: Suberoylanilide hydroxamic acid, a histone deacylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc natl Acad Sci, USA 100:2041-2046 (2003).
17. Hodgson JG, et al: A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron 23:181-192 (1999).
18. Ikeda H, et al: Expanded polyglutamine in the Machado-Joseph disease protein induces cell death in vitro and in vivo. Nature Genet 13:196-202 (1996).
19. Jones KJ, et al: Neuroprotective effects of gonadal steroids on regenerating peripheral motoneurons. Brain Res Brain Res Rev 37:372-382 (2001).
20. Katsuno M, et al: Testosterone reduction prevents phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Neuron 35:843-854 (2002).
21. Katsuno M, et al: Leuprorelin rescues polyglutamine-dependent phenotypes in a transgenic mouse model of spinal and bulbar muscular atrophy. Nature Med 9:768-773 (2003).
22. Kennedy WR, et al: Progressive proximal spinal and bulbar muscular atrophy of late onset. A sex-linked recessive trait. Neurology 18:671-680 (1968).
23. Klement IA, et al: Ataxin-1 nuclear localization and aggregation: role in polyglutamine-induced disease in SCA1 transgenic mice. Cell 95:41-53 (1998).
24. Kobayashi Y, et al: Caspase-3 cleaves the expanded androgen receptor protein of spinal and bulbar muscular atrophy in a polyglutamine repeat length-dependent manner. Biochem biophys Res Commun 252:145-150 (1998).
25. Kobayashi Y, et al: Chaperones Hsp70 and Hsp40 suppress aggregate formation and apoptosis in cultured neuronal cells expressing truncated androgen receptor protein with expanded polyglutamine tract. J biol Chem 275:8772-8778 (2000).
26. Kobayashi Y, Sobue G: Protective effect of chaperones on polyglutamine diseases. Brain Res Bull 56:165-168 (2001).
27. La Spada AR, et al: Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature 352:77-79 (1991).
28. La Spada AR, et al: Meiotic stability and genotype-phenotype correlation of the trinucleotide repeat in X-linked spinal and bulbar muscular atrophy. Nature Genet 2:301-304 (1992).
29. La Spada AR, et al: Androgen receptor YAC transgenic mice carrying CAG 45 alleles show trinucleotide repeat instability. Hum molec Genet 7:959-967 (1998).
30. Li M, et al: Nuclear inclusions of the androgen receptor protein in spinal and bulbar muscular atrophy. Ann Neurol 44:249-254 (1998).
31. Li M, et al: Nonneural nuclear inclusions of androgen receptor protein in spinal and bulbar muscular atrophy. Am J Pathol 153:695-701 (1998).
32. Lieberman AP, et al: Altered transcriptional regulation in cells expressing the expanded polyglutamine androgen receptor. Hum molec Genet 11:1967-1976 (2002).
33. MacLean HE, et al: Defects of androgen receptor function: from sex reversal to motor neuron disease. Mol Cell Endocr 112:133-141 (1995).
34. Mangiarini L, et al: Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87:493-506 (1996).
35. Mariotti C, et al: Phenotypic manifestations associated with CAG-repeat expansion in the androgen receptor gene in male patients and heterozygous females: a clinical and molecular study of 30 families. Neuromuscul Disord 10:391-397 (2000).
36. McCampbell A, et al: CREB-binding protein sequestration by expanded polyglutamine. Hum molec Genet 9:2197-2202 (2000).
37. McManamny P, et al: A mouse model of spinal and bulbar muscular atrophy. Hum molec Genet 11:2103-2111 (2002).
38. Merry DE, et al: Toward a mouse model for spinal and bulbar muscular atrophy: effect of neuronal expression of androgen receptor in transgenic mice. (abstract) Am J hum Genet 59 (suppl):A271 (1996).
39. Merry DE, et al: Cleavage, aggregation and toxicity of the expanded androgen receptor in spinal and bulbar muscular atrophy. Hum molec Genet 7:693-701 (1998).
40. Merry DE: Molecular pathogenesis of spinal and bulbar muscular atrophy. Brain Res Bull 56:203-207 (2001).
41. Mhatre AN, et al: Reduced transcriptional regulatory competence of the androgen receptor in X-linked spinal and bulbar muscular atrophy. Nature Genet 5:184-188 (1993).
42. Nasir J, et al: Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes. Cell 81:811-823 (1995).
43. Neuschmid-Kaspar F, et al: CAG-repeat expansion in androgen receptor in Kennedy's disease is not a loss of function mutation. Mol Cell Endocrinol 117:149-156 (1996).
44. Nucifora FC Jr, et al: Interference by huntingtin and atrophin-1 with CBP-mediated transcription leading to cellular toxicity. Science 291:2423-2428 (2001).
45. Peters MF, et al: Nuclear targeting of mutant Huntingtin increases toxicity. Mol Cell Neurosci 14:121-128 (1999).
46. Reddy PH, et al: Behavioural abnormalities and selective neuronal loss in HD transgenic mice expressing mutated full-length HD cDNA. Nature Genet. 20:198-202 (1998).
47. Rigamonti D, et al: Wild-type huntingtin protects from apoptosis upstream of caspase-3. J Neurosci 20:3705-3713 (2000).
48. Ross CA: Polyglutamine pathogenesis: emergence of unifying mechanisms for Huntington's disease and related disorders. Neuron 35:819-822 (2002).
49. Rubinsztein DC: Lessons from animal models of Huntington's disease. Trends Genet 18:202-209 (2002).
50. Saudou F, et al: Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell 95:55-66 (1998).
51. Schmidt BJ, et al: Expression of X-linked bulbospinal muscular atrophy (Kennedy disease) in two homozygous women. Neurology 59:770-772 (2002).
52. Sengelaub DR, et al: Hormonal control of neuron number in sexually dimorphic spinal nuclei of the rat: II. Development of the spinal nucleus of the bulbocavernosus in androgen-insensitive (Tfm) rats. J Comp Neurol 280:630-636 (1989).
53. Simeoni S, et al: Motoneuronal cell death is not correlated with aggregate formation of androgen receptors containing an elongated polyglutamine tract. Hum molec Genet 9:133-144 (2000).
54. Sobue G, et al: X-linked recessive bulbospinal neuronopathy. A clinicopathological study. Brain 112:209-232 (1989).
55. Sobue G, et al: Subclinical phenotypic expressions in heterozygous females of X-linked recessive bulbospinal neuronopathy. J Neurol Sci 117:74-78 (1993).
56. Steffan JS, et al: The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. Proc natl Acad Sci, USA 97:6763-6768 (2000).
57. Steffan JS, et al: Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature 413:739-743 (2001).
58. Stenoien DL, et al: Polyglutamine-expanded androgen receptors form aggregates that sequester heat shock proteins, proteasome components and SRC-1, and are suppressed by the HDJ-2 chaperone. Hum molec Genet 8:731-741 (1999).
59. Takeyama K, et al: Androgen-dependent neurodegeneration by polyglutamine-expanded human androgen receptor in Drosophila. Neuron 35:855-864 (2002).
60. Tanaka F, et al: Founder effect in spinal and bulbar muscular atrophy (SBMA). Hum molec Genet 5:1253-1257 (1996).
61. Tanaka F, et al: Tissue-specific somatic mosaicism in spinal and bulbar muscular atrophy is dependent on CAG-repeat length and androgen receptor-gene expression level. Am J hum Genet 65:966-973 (1999).
62. Tobin AJ, Signer ER: Huntington's disease: the challenge for cell biologists. Trends Cell Biol. 10:531-536 (2000).
63. Zhou ZX, et al: The androgen receptor: an overview. Recent Prog Horm Res 49:249-274 (1994).
64. Zhou ZX, et al: Specificity of ligand- dependent androgen receptor stabilization: receptor domain interactions influence ligand dissociation and receptor stability. Mol Endocrinol 9:208-218 (1995).
65. Zoghbi HY, Orr HT: Glutamine repeats and neurodegeneration. A Rev Neurosci 23:217-247 (2000).